



22nd October 2025

Quarterly Reporting

The Australian Stock Exchange (ASX) has advised SomnoMed Limited ('SOM' or 'the Company') that it is no longer required to lodge quarterly activity and cashflow reports under Listing Rules 4.7B and 4.7C.

Due to the timing of this change the Company will still release a quarterly update for Q1 FY26, after which SomnoMed will transition to reporting on a half-year and full-year basis.

SomnoMed will release its Q1 FY26 quarterly update on 30 October 2025.

Authorised by the Company Secretary of SomnoMed Limited

About SomnoMed SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 1 million patients in over 20 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

Investor Enquiries

Investor Relations

ir@somnomed.com